Estonia's Tallinna Farmaatsiatehas says it hopes to start production ata new antibiotics plant in Kirna in central Estonia this month, reports the Baltic News Service.
Board chairman Priit Kivi was reported as saying that the firm's plant in Tallinn does not produce antibiotics, so the volume of production at Kirna should be considerable. A new ointment production facility has also recently started up at the Tallinn plant. The company forecasts a 48.1 million kroon ($3.4 million) profit this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze